DM Clinical Research

1. Moderna TX, Inc. $15,815,999 4,238 payments
2. Regeneron Pharmaceuticals, Inc. $3,628,271 135 payments
3. AstraZeneca UK Limited $947,114 13 payments
4. Merck Sharp & Dohme Corporation $596,453 24 payments
5. Kiniksa Pharmaceuticals, Ltd. $541,967 551 payments
6. Novartis Pharmaceuticals Corporation $154,009 4 payments
7. Ucb SA $118,356 2 payments
8. Pfizer Inc. $96,026 96 payments
9. Kiniksa Pharmaceuticals International, plc $54,755 103 payments
10. AstraZeneca Pharmaceuticals LP $44,400 2 payments

1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $8,490,627 212 payments
2. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $2,446,375 70 payments
3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,105,928 3,777 payments
4. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $1,111,494 17 payments
5. A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $822,196 28 payments
6. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $711,933 16 payments
7. A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease $674,000 5 payments
8. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $663,724 37 payments
9. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $538,345 19 payments
10. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $521,482 42 payments

1. Other $3,969 57 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.